Abstract.
Rasagiline is an antiapoptotic compound with neuroprotective potential. We examined its neuroprotective effect alone and in combination with the putative glutamate release blocker riluzole in the G93A model of familial amyotrophic lateral sclerosis (fALS). Endpoints of experimental treatment were survival and motor activity. The drug had a significant dose-dependent therapeutic effect on both preclinical and clinical motor function and survival of the animals. We also found that the combination of rasagiline with riluzole is safe and increases survival by about 20 % in a dosedependent manner. Therefore, we conclude that the combination of rasagiline and riluzole is a promising clinical combination for the improvement of current neuroprotective treatment strategies of ALS.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ludolph AC, Meyer T, Riepe MW (1999) Antiglutamate therapy in ALS—which is the next step? J Neur Transm (Suppl) 55:79–96
Brookes BR, Belden DS, Roelke K, et al. (2001) Survival in non-riluzole treated amyotrophic lateral sclerosis (ALS)—motor neuron disease (MND) patients with disease onset before and since 1996 is identical: A clinic-based epidemiologic study. Amyotroph Lat Scler Other Motor Disord (Suppl 2) 2:60–61
Traynor BJ, Alexander M, Corr B (2003) An outcome study of riluzole in amyotrophic lateral sclerosis—a population-based study in Ireland. J Neurology 250:473–479
Turner MR, Bakker M, Sham P, Shaw CE, Leigh PN, Al-Chalabi A (2002) Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lat Scler Other Motor Disord 1:15–21
Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX (1994) Motor neuron degeneration in mice that express a human superoxide dismutase mutation. Science 264:1772–1775
Gurney ME, Cutting FB, Zhai P, Doble A, Taylor CP, Andrus PK, Hall ED (1996) Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 39:147–157
Ferrante RJ, Shinobu LA, Schulz JB, Matthews RT, Thomas CE, Kowall NW, Gurney ME, Beal MF (1997) Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. Ann Neurol 42:326–334
Kong J, Xu Z (1998) Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J Neurosci 18:3241–3250
Wong PC, Pardo CA, Borchelt DR, et al. (1995) An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14:1105–1116
Vielhaber S, Kunz D, Winkler K, et al. (2000) Mitochondrial DNA abnormalities in skeletal muscle of patients with sporadic amyotrophic lateral sclerosis. Brain 123:1339–1348
Youdim MBH, Gross A, Finberg JPM (2001) Rasagiline (N-propargyl-1R(+)-aminoindan), a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 132:500–506
Maruyama W, Akao Y, Youdim MBH, David BA, Naoi M (2001) Transfectionenforced bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. J Neurochem 78:727–735
Eliash S, Speiser Z, Cohen S (2001) Rasagiline and its (S) enantiomer increase survival and prevent stroke in salt-loaded stroke-prone spontaneously hypertensive rats. J Neur Transm 108:909–923
Speiser Z, Mayk A, Eliash S, Cohen S (1999) Studies with rasagiline, a monoamine oxidase-B inhibitor, in experimental focal ischemia in the rat. J Neur Transm 106:593–606
Huang W, Chen Y, Shohani E, Weinstock M (1999) Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur J Pharmacol 336:127–135
Doble A (1996) The pharmacology and mechanism of action of riluzole. Neurology (Suppl 1) 47:S233–S241
Maruyama W, Akao Y, Youdim MBH, Naoi M (2000) Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022. J Neur Transm (Suppl) 60:171–186
Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V (1996) Doseranging study of riluzole in amyotrophic lateral sclerosis. Lancet 347:1425–1431
Cleveland DW, Rothstein JD (2001) From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 11:806–819
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Waibel, S., Reuter, A., Malessa, S. et al. Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. J Neurol 251, 1080–1084 (2004). https://doi.org/10.1007/s00415-004-0481-5
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00415-004-0481-5